Literature DB >> 20512522

Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis.

Giuseppe De Luca1, Guido Parodi, David Antoniucci.   

Abstract

Recent studies suggests that bleeding complications are associated with worse clinical outcome and survival among patients undergoing coronary angioplasty. Thus, in the last years increasing interests have been focused on strategies to prevent bleeding complications. The administration of protamine after coronary stenting for early sheath removal seems very attractive to minimize local and systemic bleeding complications. Thus, the aim of the current study is to perform a meta-analysis of randomized and non-randomized trials evaluating the benefits and safety of protamine administration after coronary angioplasty. The literature was scanned by formal searches of electronic databases (MEDLINE and CENTRAL) from January 1990 to December 2009. The following key words were used: coronary angioplasty, primary angioplasty, coronary stenting, protamine, heparin neutralization, bleeding complications. Primary endpoints were death and major bleeding complications, respectively. Secondary endpoint was myocardial infarction. A total of 5 trials, 2 randomized and 3 non randomized were included in the meta-analysis, involving 6,762 patients (4,913 or 72.6% in the protamine group and 1,949 or 27.4% in the standard group). Protamine administration was not associated with difference in short-term mortality (2.8% vs. 2.7%, OR [95% CI] = 0.97 [0.69-1.37], P = 0.88, p(het) = 1.0), but with a significant reduction in major bleeding complications (2.4% vs. 4.1%, OR [95% CI] = 0.51 [0.37-0.69], P < 0.0001, p(het) = 0.53, NNT = 58.8). No difference was observed myocardial infarction (0.9% vs. 0.8%, OR [95% CI] = 1.14 [0.63-2.07], P = 0.66, p(het) = 0.89). This meta-analysis shows that protamine administration after percutaneous coronary intervention seems to be safe and associated with a significant reduction in major bleeding complications. Pending the results of larger randomized trials, its use may be considered after coronary angioplasty.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512522     DOI: 10.1007/s11239-010-0482-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  21 in total

Review 1.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.

Authors:  D Moher; D J Cook; S Eastwood; I Olkin; D Rennie; D F Stroup
Journal:  Lancet       Date:  1999-11-27       Impact factor: 79.321

2.  Impact of heparin neutralization by protamine on restenosis after coronary stent implantation.

Authors:  Hideaki Kaneda; Jun Suzuki; George Hosokawa; Shinji Tanaka; Yoshitaka Hiroe; Shigeru Saito
Journal:  Int J Cardiol       Date:  2005-10-20       Impact factor: 4.164

3.  Protamine induces endothelium-dependent vasodilatation of the pulmonary artery.

Authors:  P R Evora; P J Pearson; H V Schaff
Journal:  Ann Thorac Surg       Date:  1995-08       Impact factor: 4.330

4.  In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.

Authors:  M Pan; J Suárez de Lezo; A Medina; M Romero; E Hernández; J Segura; F Melian; F Wangüemert; M Landin; F Benítez; M Amat; F Velasco; A Torres
Journal:  Am J Cardiol       Date:  1997-11-15       Impact factor: 2.778

5.  Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.

Authors:  Gregg W Stone; Michel Bertrand; Antonio Colombo; George Dangas; Michael E Farkouh; Frederick Feit; Alexandra J Lansky; A Michael Lincoff; Roxana Mehran; Jeffrey W Moses; Magnus Ohman; Harvey D White
Journal:  Am Heart J       Date:  2004-11       Impact factor: 4.749

6.  Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial.

Authors:  Roxana Mehran; Stuart J Pocock; Gregg W Stone; Tim C Clayton; George D Dangas; Frederick Feit; Steven V Manoukian; Eugenia Nikolsky; Alexandra J Lansky; Ajay Kirtane; Harvey D White; Antonio Colombo; James H Ware; Jeffrey W Moses; E Magnus Ohman
Journal:  Eur Heart J       Date:  2009-04-07       Impact factor: 29.983

7.  Safety of heparin reversal with protamin and immediate sheath removal after coronary angioplasty.

Authors:  F Lohne; N E Kløw; S Stavnes; M Brekke; P Hoffmann; K H Stensaeth; E Søvik; M S Pettersen
Journal:  Acta Radiol       Date:  2004-04       Impact factor: 1.990

8.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.

Authors:  Roxana Mehran; Alexandra J Lansky; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; S Chiu Wong; Eugenia Nikolsky; Louise Gambone; Lynn Vandertie; Helen Parise; George D Dangas; Gregg W Stone
Journal:  Lancet       Date:  2009-08-28       Impact factor: 79.321

9.  Immediate protamine administration and sheath removal following percutaneous coronary intervention: a prospective study of 429 patients.

Authors:  John Ducas; Michael C Y Chan; Anthony Miller; Tarek Kashour
Journal:  Catheter Cardiovasc Interv       Date:  2002-06       Impact factor: 2.692

Review 10.  Protamine: a review of its toxicity.

Authors:  J C Horrow
Journal:  Anesth Analg       Date:  1985-03       Impact factor: 5.108

View more
  4 in total

1.  Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience.

Authors:  Giuseppe De Luca; Monica Verdoia; Alon Schaffer; Harry Suryapranata; Guido Parodi; David Antoniucci; Paolo Marino
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

Review 2.  Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

Authors:  Giuseppe De Luca; Stefano Savonitto; Arnoud W J van't Hof; Harry Suryapranata
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

3.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27

4.  Safety and efficacy of immediate heparin reversal with protamine after complex percutaneous coronary intervention.

Authors:  Jin Hee Choi; Kook Jin Chun; Soon Myung Jung; Soo Yong Lee; Min Ku Chon; Sang Hyun Lee; Ki Won Hwang; Jeong Su Kim; Yong-Hyun Park; June Hong Kim
Journal:  BMC Cardiovasc Disord       Date:  2022-05-10       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.